KRAS G13C

Clinical trials for KRAS G13C explained in plain language.

Never miss a new study

Get alerted when new KRAS G13C trials appear

Sign up with your email to follow new studies for KRAS G13C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill targets hard-to-treat cancers with KRAS and BRAF mutations

Disease control Recruiting now

This study tests an experimental oral drug, S241656, in people with advanced cancers (like lung, colon, or pancreatic) that have certain gene changes (KRAS, BRAF, or related). The drug is taken daily in 28-day cycles, either alone or with other cancer treatments. The goal is to f…

Matched conditions: KRAS G13C

Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

KRAS G13C

Get alerted when new KRAS G13C trials appear

New pill targets hard-to-treat cancers with KRAS and BRAF mutations